European directive will halt use of MRI scans; cancer diagnosis and treatment w... ( Barcelona Spain: Implementation of th...)

European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer

Date:9/24/2007

Barcelona, Spain: Implementation of the Physical Agents (Electromagnetic Fields) Directive 2004/40/EC in all Member States could effectively halt the use of magnetic resonance imaging (MRI), an important tool in cancer diagnosis, treatment, and research, a scientist told a press conference at the European Cancer Conference (ECCO 14) today (Monday September 24). The Directive is due to be implemented across Europe by April 2008.

The Directive was drafted by DG Employment, with the aim of minimising workers exposure to electromagnetic fields (EMF). Currently eight million MRI patient examinations per year are carried out in Europe, said Professor Dag Rune Olsen, who works in experimental radiation therapy at the Norwegian Radiation Hospital, Oslo, Norway, and is chairman of the physics committee of the European Society for Therapeutic Radiology and Oncology (ESTRO). But these are likely to have to stop, since the Directive sets limits to occupational radiation exposure which will mean that anyone working or moving near MRI equipment will breach them, thus making it possible for them to sue their employers. Even those maintaining or servicing the equipment may be affected, he said.

A British study into operator exposure to electromagnetic fields from MRI, published by the Heath and Safety Executive in June 2007, and carried out by Professor Stuart Crozier from Brisbane University, Australia, found that anyone standing within about one metre of an MRI scanner in use would breach the exposure limits laid down in the directive. The Commission has accepted this, and said that it will consider the HSE report together with the study it has commissioned itself, and which is due for publication in October 2007, when deciding whether and how to propose amendments to the directive or to extend the implementation period.

But they may already be too late, said Professor Olsen. Slovakia has already implemented the directive, on the grounds that it wa
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Conference
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Lung Cancer Deaths Declining In Men But Not Women In European Countries
2. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
3. European Countries To Fund $4 Billion For Vaccination For Poor Children’
4. Nanotechnology Revolution To Be Spearheaded By European Union
5. Detection of Weak strains of bird flu virus – Target of European Unio
6. Europe On High Bird Flu Alert: European Commission
7. Slovenia, Bulgaria, Greece Face Bird Flu Threat: European Union
8. Heart Brakes: Hearts in European Union Invite Health Attention
9. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
10. European Union: Poultry producers Need Aid to Survive Bird flu crisis
11. Control And Prevention Of Three Diseases To Be Discussed: European Commission

Post Your Comments:

(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...

(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...

(Date:5/21/2013)... recently published in the New England Journal of ... the University of Colorado School of Medicine finds that ... be used to identify individuals at risk for this ... common variant of the gene for mucin-5B, a protein ... the bronchial tubes. While this variant of the MUC5B ...

Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Researchers find genetic risk factor for pulmonary fibrosis

... ... ... ... ...

... ... motorist and developed tinnitus, or severe ringing in her ears; she was granted compensation for ... ... carrier represented by East Tennessee attorney Brack Terry of Terry, Terry & Stapleton ...

... ... than £200 this month because of the cold snap. After one of the coldest Januarys in ... £226 – a £70 hike. , ... February 19, 2010 -- Britons are facing record energy bills of more than £200 this month ...

... Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate ... and wrist enabling more targeted therapies unique to each ... of the American Journal of Roentgenology . Contrast-enhanced ... internal bodily structures. Rheumatoid ...

... ... ... ... ...

MDS Announces Substantial Issuer Bid East Tennessee Attorney Brack Terry Obtains $120,000 Jury Award For Injured Mail Carrier It's Snow Joke as UK Gas and Electricity Bills Hit Record Highs -- Energyhelpline Calls for “Significant” Price Cuts Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis FDA Cancer Drug Approval Rate Highlighted in JNCI 'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand

(Date:5/21/2013)... , May 21, 2013 Accuray Incorporated ... the publication of study results involving hundreds of ... Radiosurgery System, the most widely used form of ... followed 304 patients for a median of 5 ... found that 97 percent of patients with low-risk ...

(Date:5/21/2013)... Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...

Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2

[0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment [0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference

... N.J., Dec. 15 Synvista Therapeutics, Inc. (NYSE ... dosed the first patient in a 30-patient Phase 2 ... patients with psoriasis. The trial is planned to be ... assess the efficacy of topical SYI-2074, applied twice daily, ...

... DIEGO, Dec. 14 bioTheranostics, a bioMerieux company,that ... in,oncology, reported today findings from three studies using ... of disease recurrence in,individual patients. Data from the ... Breast Cancer Symposium (SABCS). , ...

Cached Medicine Technology:Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 2 Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Chlamydia pneumoniae Antibodies, IgG & IgM by ELISA Chlamydia Group Antibody, Screen Chimerism, Recipient Pre-Transplant Chenodeoxycholic Acid